We will survive

 

[Back] [ Home] [Top]

Home What Is ALS? Symptoms Diagnosis FAQ's ALS Facts ALS Terms Treatments ALS Clinic Team Pressure sores Nutrition Assistive Devices Neck Support Communication Respiratory ALS Tips Coping Resources Research Stem Cell Guidelines Caregiver Hospice News Center Advocacy Links Inspiration Quotes Morrie Schwartz Profiles Memorial My Story Lou Gehrig Search MEDLINEplus Tope's Hope Disclaimer Privacy Statement

This website is accredited by Health On the Net Foundation. Click to verify.

We comply with the HONcode standard for trustworthy health
information:
verify here.

Scripts by
Dynamic Drive

Site Meter

Focus on ALS
has been self-funded since
 1997--2008

Scroll up
Scroll down
Back -Top

FDA halts CytRx's trial on Lou Gehrig's disease drug

Source: Financial News - Yahoo! Finance

Tuesday January 22, 11:38 am ET

CytRx Corp. was told by the Food and Drug Administration to halt its clinical trial of a drug to treat Lou Gehrig's disease based on the need for additional analysis of previous animal studies involving the drug arimoclomol, the company said Tuesday.

CytRx said in a relase that it has asked for further clarification from the FDA, and said that "arimoclomol has been shown to be safe and well-tolerated after being administered to about 185 study volunteers."

Lou Gehrig's disease, also known as amyotrophic lateral sclerosis or ALS, is a progressive condition that affects nerve cells in the brain and spinal cord.

Los Angeles-based CytRx (NASDAQ: CYTR - News) biopharmaceutical research and development company.

Published January 22, 2008 by Los Angeles Business from bizjournals

[Back] [Home] [Top]

~Best viewed with a positive attitude~